The Current State of NAFLD Treatment and Need for Novel Therapies

Non-alcoholic fatty liver disease () has reached epidemic proportions globally, affecting approximately 25-30% of the Hong Kong population according to recent studies from the Hong Kong Liver Health Association. The current therapeutic landscape remains frustratingly limited, with lifestyle modifications serving as the cornerstone of management and no approved pharmacological therapies specifically targeting NAFLD progression. This gap in treatment options becomes particularly concerning when considering that approximately 20-30% of NAFLD patients progress to non-alcoholic steatohepatitis (NASH), with subsequent risks of cirrhosis, hepatocellular carcinoma, and liver-related mortality. The growing recognition of NAFLD as a multisystem disease that increases cardiovascular and metabolic risks further underscores the urgent need for effective interventions. While conventional approaches have focused on weight management and metabolic control, the complex pathophysiology of NAFLD demands more targeted strategies that address the multiple hits involved in disease progression.

Targeting Specific Pathways in NAFLD Treatment

FXR Agonists: Regulating Bile Acid Metabolism

Farnesoid X receptor (FXR) agonists represent one of the most promising therapeutic classes in NAFLD management. These compounds work by activating the FXR nuclear receptor, which plays a central role in regulating bile acid synthesis, glucose metabolism, and lipid homeostasis. Obeticholic acid (OCA), the most advanced FXR agonist in clinical development, has demonstrated significant histological improvement in NASH patients across multiple trials. The REGENERATE study showed that OCA 25mg daily achieved the primary endpoint of fibrosis improvement by at least one stage without worsening of NASH in 23.1% of patients compared to 11.9% in the placebo group. However, concerns regarding pruritus and alterations in lipid profiles have prompted the development of next-generation FXR agonists with improved safety profiles. Novel agents like tropifexor and cilofexor are being evaluated for their potential to provide similar efficacy with reduced side effects, potentially revolutionizing how we approach liver protection in metabolic liver diseases.

PPAR Agonists: Multi-Faceted Metabolic Modulators

Peroxisome proliferator-activated receptor (PPAR) agonists target a group of nuclear receptors that regulate glucose and lipid metabolism, inflammation, and fibrogenesis. The pan-PPAR agonist lanifibranor has shown particularly promising results in the NATIVE phase IIb trial, demonstrating significant resolution of NASH without worsening of fibrosis. Specifically, 55% of patients receiving lanifibranor 1200mg daily achieved NASH resolution compared to 33% in the placebo group. The dual PPARα/δ agonist elafibranor, while showing mixed results in earlier trials, continues to be investigated in selected patient populations. What makes PPAR agonists particularly attractive is their potential to address multiple aspects of NAFLD pathophysiology simultaneously—improving insulin sensitivity, reducing hepatic steatosis, and decreasing inflammation. This multi-target approach represents a significant advancement over conventional that typically address single pathways.

ASK1 Inhibitors: Addressing Cellular Stress and Inflammation

Apoptosis signal-regulating kinase 1 (ASK1) inhibitors represent a novel approach targeting the inflammatory and fibrotic components of NASH. ASK1 is activated in response to various cellular stresses, including oxidative and endoplasmic reticulum stress, leading to activation of p38 and JNK pathways that promote hepatocyte apoptosis, inflammation, and fibrosis. Selonsertib, the most extensively studied ASK1 inhibitor, demonstrated antifibrotic activity in phase II trials, though it failed to meet primary endpoints in phase III studies. Despite these setbacks, the ASK1 pathway remains biologically validated, and research continues into optimizing this therapeutic approach, potentially through combination strategies. The investigation of ASK1 inhibitors highlights the evolving understanding that effective NAFLD treatment must address the complex interplay between metabolic dysfunction, oxidative stress, and inflammatory signaling.

ACC Inhibitors: Targeting De Novo Lipogenesis

Acetyl-CoA carboxylase (ACC) inhibitors target a key enzyme in de novo lipogenesis (DNL), the process by which the liver produces fatty acids from carbohydrates. In NAFLD patients, DNL is significantly upregulated, contributing substantially to hepatic fat accumulation. Firsocostat, an ACC inhibitor, has demonstrated potent reductions in hepatic fat fraction as measured by MRI-PDFF in clinical trials. However, compensatory increases in triglyceride levels have been observed, leading to exploration of combination approaches with other agents. The development of ACC inhibitors represents a direct approach to addressing the fundamental metabolic disturbance in NAFLD and offers a mechanism distinct from currently available liver health supplements. Ongoing research focuses on maximizing hepatic specificity while minimizing systemic effects to optimize the therapeutic window of these compounds.

Combination Therapies: Addressing Multiple Pathways Simultaneously

The complexity of NAFLD pathophysiology has led to growing recognition that combination therapies targeting multiple mechanisms simultaneously may be necessary for optimal efficacy. Several combination approaches are currently under investigation, with the most advanced being the pairing of FXR agonists with ACC inhibitors. The phase IIb ATLAS trial evaluated the combination of firsocostat (ACC inhibitor) and cilofexor (FXR agonist) with or without selonsertib (ASK1 inhibitor) in patients with bridging fibrosis or compensated cirrhosis due to NASH. Results demonstrated that the dual combination of firsocostat and cilofexor led to greater improvements in liver histology compared to monotherapies. Other promising combinations include PPAR agonists with FXR agonists or GLP-1 receptor agonists, creating complementary mechanisms that address metabolic dysfunction, inflammation, and fibrosis simultaneously. This multi-pronged approach represents a paradigm shift from single-target interventions and may ultimately provide the comprehensive liver protection needed to alter the natural history of advanced NAFLD.

Biomarkers and Diagnostics: Enabling Early Detection and Monitoring

The development of reliable biomarkers and non-invasive diagnostic tools represents a critical frontier in NAFLD management. Current diagnostic approaches often rely on liver biopsy, which has limitations including invasiveness, sampling variability, and patient reluctance. Emerging blood-based biomarkers such as PRO-C3 (a marker of fibrogenesis), cytokeratin-18 fragments (a marker of apoptosis), and various miRNA signatures show promise for non-invasive assessment of disease activity and stage. In Hong Kong, researchers at the Chinese University of Hong Kong have developed and validated the MAST (MRI-AST) score, which combines MRI-proton density fat fraction with AST levels to accurately identify patients with advanced fibrosis. Additionally, vibration-controlled transient elastography (FibroScan) has become increasingly available in clinical practice, providing reliable assessment of liver stiffness and controlled attenuation parameter (CAP) for steatosis evaluation. These advances in diagnostics are crucial not only for identifying at-risk patients but also for monitoring treatment response in clinical trials and eventually in practice, potentially reducing reliance on repeated liver biopsies.

Lifestyle Interventions as the Therapeutic Foundation

Despite exciting pharmacological developments, lifestyle interventions remain the foundation of NAFLD management. Comprehensive lifestyle modification programs in Hong Kong have demonstrated that 7-10% weight loss can achieve NASH resolution in up to 90% of patients and fibrosis improvement in 45% of patients. The Mediterranean diet has shown particular benefit, with studies demonstrating significant reductions in liver fat independent of weight loss. Structured exercise programs, combining both aerobic and resistance training, have been shown to reduce hepatic steatosis by approximately 20-30% even with minimal weight loss. The emerging challenge lies in effectively integrating lifestyle interventions with pharmacological therapies to achieve synergistic benefits. Future treatment paradigms will likely combine personalized dietary approaches, structured physical activity, and targeted pharmacotherapy based on individual disease characteristics and genetic predispositions. This integrated approach acknowledges that while novel therapeutics represent important advances, they will be most effective when built upon a solid foundation of lifestyle modification.

Challenges and Future Directions in NAFLD Therapeutics

The path to approved NAFLD therapies faces several significant challenges. The heterogeneity of NAFLD presents difficulties in patient selection for clinical trials and may ultimately require different treatment approaches based on predominant pathophysiology (metabolic, inflammatory, or fibrotic). Regulatory requirements for drug approval continue to evolve, with ongoing debates about appropriate endpoints—histological improvement versus hard clinical outcomes. Additionally, long-term safety concerns must be thoroughly addressed, particularly for therapies targeting fundamental metabolic pathways. The future of NAFLD management likely lies in personalized medicine approaches that integrate genetic, metabolic, and environmental factors to match patients with optimal therapies. Polygenic risk scores incorporating variants in PNPLA3, TM6SF2, MBOAT7, and GCKR may eventually guide therapeutic selection. Furthermore, digital health technologies including wearable devices and mobile applications offer opportunities to enhance monitoring of lifestyle interventions and medication adherence. As research advances, the goal remains developing safe, effective, and accessible treatments that can be implemented across diverse healthcare systems including Hong Kong's unique medical landscape.

The Promising Horizon of NAFLD Management

The landscape of NAFLD treatment is rapidly evolving, with multiple therapeutic classes demonstrating potential to meaningfully alter disease progression. From FXR agonists that target bile acid metabolism to ACC inhibitors that directly address hepatic lipogenesis, the pipeline reflects our growing understanding of NAFLD pathophysiology. Combination approaches that simultaneously target metabolic dysfunction, inflammation, and fibrosis represent particularly promising strategies that may finally provide the comprehensive liver protection needed for this complex disease. Parallel advances in non-invasive diagnostics will enable better patient stratification and treatment monitoring, potentially transforming clinical management paradigms. While challenges remain in drug development and implementation, the collective progress across multiple therapeutic areas provides genuine hope for improved outcomes for the millions affected by NAFLD worldwide. As research continues to unfold, the prospect of effective pharmacological interventions combined with lifestyle foundation promises a future where NAFLD can be managed effectively, preventing progression to advanced liver disease and its associated complications.